Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | HINT1 | P49773 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482861 | 0.89 | TACR1 (0.42) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL22482959 | 0.89 | TACR1 (0.42) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL22482844 | 0.89 | TACR1 (0.42) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL22482958 | 0.89 | TACR1 (0.42) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL18894572 | 0.89 | TACR1 (0.42) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL24080579 | 0.85 | TACR1 (0.39) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL24080578 | 0.85 | TACR1 (0.39) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL11245043 | 0.85 | P2RY6 (0.54) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL11245047 | 0.85 | P2RY6 (0.54) | P2RY6P2RY14NT5EHINT1LMNA | |
| SCHEMBL11244533 | 0.84 | NMBR (0.48) | HINT1LMNAMAPTTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125820-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-28 | — | — | US | disclosed |
| US-11191774-B2 | Drug formulations for cancer treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200306284-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | disclosed |
| EP-3380082-A2 | DRUG FORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017091767-A2 | DRUG FORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125820-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | RNMT, NTPCR, SYNCRIP | P2RY6 1309/4885P2RY14 3673/4885NT5E 71/4885 |
| US-20200306284-A1 | DRUG FORMULATIONS FOR CANCER TREATMENT | RNMT, NTPCR, SYNCRIP | P2RY6 1309/4885P2RY14 3673/4885NT5E 71/4885 |
| US-11191774-B2 | Drug formulations for cancer treatment | RNMT, NTPCR, SYNCRIP | P2RY6 1309/4885P2RY14 3673/4885NT5E 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.